Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.

NCT01927965 is registered in ClinicalTrials.gov with Minneamrita Therapeutics LLC as lead sponsor.

NCT NCT01927965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01927965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.
Lead sponsor
Minneamrita Therapeutics LLC
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
December 31, 2016
Enrollment
45 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal tumors